Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CART-EGFR-IL13Ra2 cells |
| Synonyms | |
| Therapy Description |
CART-EGFR-IL13Ra2 cells are autologous T-lymphocytes engineered to express chimeric antigen receptors (CARs) that target EGFR epitope 806 and IL13Ra2, which potentially induce toxicity in tumor cells expressing EGFR or IL13Ra2 (PMID: 40451950, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CART-EGFR-IL13Ra2 cells | IL13RA2 Immune Cell Therapy 7 | CART-EGFR-IL13Ra2 cells are autologous T-lymphocytes engineered to express chimeric antigen receptors (CARs) that target EGFR epitope 806 and IL13Ra2, which potentially induce toxicity in tumor cells expressing EGFR or IL13Ra2 (PMID: 40451950, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06973096 | Phase I | CART-EGFR-IL13Ra2 cells | CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy | Recruiting | USA | 0 |
| NCT07209241 | Phase I | CART-EGFR-IL13Ra2 cells | Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM | Recruiting | USA | 0 |
| NCT05168423 | Phase I | CART-EGFR-IL13Ra2 cells | CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM | Active, not recruiting | USA | 0 |